Re-linking untreated Hepatitis C patients to care through telemedicine
Re-linking People With Diagnosed But Untreated HCV to Care in a Community-based Substance-use Telemedicine Program
This study is testing whether a telemedicine program can help people with untreated Hepatitis C get the care they need, especially those who also struggle with substance use.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Sex | All |
| Sponsor | trueNorth Medical Centres Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT06349902 on ClinicalTrials.gov |
What this trial studies
This observational study aims to re-link individuals diagnosed with untreated Hepatitis C (HCV) to care using a community-based substance-use telemedicine program. It includes both retrospective chart reviews to identify untreated patients and a prospective cohort to evaluate treatment outcomes such as linkage to care and cure rates. The study focuses on individuals over 18 with a positive HCV RNA result who have not completed Direct-Acting Antiviral (DAA) treatment. By integrating HCV treatment with substance use care, the study seeks to improve treatment uptake among people who inject drugs (PWID). Data analysis will utilize IBM SPSS to assess the efficacy of this telemedicine approach.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 18 and older with a positive HCV RNA result who have not previously completed DAA treatment.
Not a fit: Patients who are unable or unwilling to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve access to HCV treatment for individuals with substance use issues.
How similar studies have performed: Other studies have shown success in integrating telemedicine with substance use treatment, indicating potential for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: For the retrospective chart review element of the study, inclusion criteria includes anyone who had a telemedicine visit at the community based substance use telemedicine program between January 1st 2023 and December 31st 2024. For the prospective cohort element of the study, the inclusion criteria are listed below: Aged ≥18. Ability and willingness of the participant to provide informed consent. Having a positive HCV RNA laboratory result and lacking a sufficient previous course of DAA treatment. Exclusion Criteria: For the retrospective chart review element of the study, exclusion criteria is: a consent directive to restrict access to their OLIS record. For the prospective cohort study, exclusion criteria is an inability or unwillingness of the participant to provide informed consent. -
Where this trial is running
Toronto, Ontario
- trueNorth Medical Centre — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Study coordinator: Hannah O'Reilly
- Email: hannah.oreilly@truenorthmedical.com
- Phone: 8888783563
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.